Vir granted EU commercial rights of tobevibart + elebsiran to Norgine Pharma for EU commercialization

Vir announced it has granted Norgine Pharma an exclusive license for the commercial rights to tobevibart (mAb) + elebsiran (siRNA) for the treatment of CHD in Europe, Australia, and New Zealand.  (Vir will retain all commercialization rights for tobevibart + elebsiran in the US.)

Norgine is a European specialty pharma company, with a presence in 12 European countries, Australia and New Zealand; that includes manufacturing capabilities, third party supply networks, salesforces, and marketing infrastructure.  Norgine has been expanding its rare disease portfolio through acquisitions and in-licensing, as evidenced by recent deals

Deal highlights:

• Vir will receive an initial EUR 55M payment, is eligible to receive up to EUR 495M in clinical, regulatory, and sales milestones, and will also receive tiered mid-teen to high-twenties percent royalties on net sales across Norgine’s licensed territories
• Clinical and development costs for the ongoing ECLIPSE registrational program will be shared between Vir and Norgine, with Norgine contributing ~25% of go-forward external expenses
• As a result, Vir has extended its runway into Q4 2027 (previously guided for mid-2027)

Vir also announced it has completed enrollment of the Ph2b ECLIPSE 3 trial (N=100; PCD: Nov 2026), which is designed to support access and reimbursement in Europe and other ex-US geographies

Now that Vir has secured an experienced EU partner and completed enrollment for ECLIPSE 3, EU commercialization of tobevibart + elebsiran has increased in likelihood of launch in Europe, following projected US launch in Q4 2027.